Literature DB >> 24196627

[In situ analyses of molecular mechanisms of colorectal carcinogenesis].

L Kriegl1.   

Abstract

The main signaling pathways of colorectal carcinogenesis encompass the classical adenoma-carcinoma sequence and the serrated route. In the classical adenoma-carcinoma sequence there are initially frequent mutations of the APC gene which lead to an activation of the WNT signaling pathway. When the WNT signaling pathway is activated β-catenin mediates the transcription of diverse factors which cause migration, invasion and proliferation of cells. Although APC mutations occur in all tumor cells, a heterogeneous distribution pattern of β-catenin is found in tumors and β-catenin also represents an important prognostic marker. A similar picture is found for γ-catenin which is expressed independently from β-catenin. Clearly more homogeneous is the expression of TCF4 and LEF1 which are the main binding partners of β-catenin and γ-catenin and are likewise important prognostic markers. The TRAIL signaling pathway is therapeutically interesting and within this pathway loss of the main receptors TRAIL-R1 and TRAIL-R2 is frequently found. Furthermore, the membranous localization of both factors correlates with a better overall survival. These results might be therapeutically relevant with respect to therapy with recombinant TRAIL molecules binding to TRAIL-R1 and TRAIL-R2. In the serrated route oncogen-induced senescence caused by mutations of the KRAS and BRAF oncogenes initially plays an important role. This senescence blockade is overcome by hypermethylation of the p16(INK4a) promoter and leads to the development of invasive tumors. The SIRT1 and c-Myc genes also contribute to progression of lesions in the serrated route and are activated through the RAS/RAF/MAPK-kinase signaling pathway as well as the WNT/β-catenin signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24196627     DOI: 10.1007/s00292-013-1821-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  30 in total

1.  The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule
Journal:  Ann Oncol       Date:  2010-05-25       Impact factor: 32.976

Review 2.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.

Authors:  J R Jass
Journal:  Histopathology       Date:  2007-01       Impact factor: 5.087

3.  γ-Catenin is an independent prognostic marker in early stage colorectal cancer.

Authors:  Jutta Maria Nagel; Lydia Kriegl; David Horst; Jutta Engel; Shiva Gautam; Christos S Mantzoros; Thomas Kirchner; Burkhard Göke; Frank Thomas Kolligs
Journal:  Int J Colorectal Dis       Date:  2010-08-25       Impact factor: 2.571

4.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

5.  Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer.

Authors:  Lydia Kriegl; Jens Neumann; Michael Vieth; Florian R Greten; Simone Reu; Andreas Jung; Thomas Kirchner
Journal:  Mod Pathol       Date:  2011-03-18       Impact factor: 7.842

6.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

7.  Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front.

Authors:  T Brabletz; A Jung; K Hermann; K Günther; W Hohenberger; T Kirchner
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

8.  Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4.

Authors:  V Korinek; N Barker; P Moerer; E van Donselaar; G Huls; P J Peters; H Clevers
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer.

Authors:  Lydia Kriegl; David Horst; Jana A Reiche; Jutta Engel; Thomas Kirchner; Andreas Jung
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

10.  Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer.

Authors:  Lydia Kriegl; Michael Vieth; Thomas Kirchner; Antje Menssen
Journal:  Oncotarget       Date:  2012-10
View more
  2 in total

1.  GEFT protein expression in digestive tract malignant tumors and its clinical significance.

Authors:  Yuanyuan Wang; Bing Zhang; Ge Gao; Yinping Zhang; Qingxin Xia
Journal:  Oncol Lett       Date:  2019-09-24       Impact factor: 2.967

2.  The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of CUL4A/4B and affects the stability of CRL4 E3 ligases in colorectal cancer.

Authors:  Wenzhu Lu; Chunmei Yang; Hongbo He; Hong Liu
Journal:  Int J Biol Sci       Date:  2020-02-04       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.